Ingredion (INGR)
NYSEConsumer StaplesPackaged FoodsSnapshot 2026-11-04
$97.36+0.60%
Close 2026-11-04 · 1-day change
NYSEConsumer StaplesPackaged FoodsSnapshot 2026-11-04
Research Workspace
Put INGR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Staples is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Adjusted EPS between $10.45 and $11.15: Comparison needs review.
View ThesisRevenue is contracting — down about 1% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIngredion's steady results must justify its low price. Revenue grew 1% in the latest quarter. The company beat its earnings estimate by 3.3%. It trades at 9.3 times earnings. Peers trade at 16.7 times earnings. The price reflects less growth than we forecast. The primary pillar is under pressure. The thesis comparison is not yet verified. Peer multiples imply a price about 21% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. INGR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 7 analysts currently covering INGR (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare INGR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| INGR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Agricultural Products & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put INGR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete acquisition of Tate & Lyle and integrate operations
Deal aligns with growth strategy and reshapes growth mix.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Complete acquisition of Tate & Lyle and integrate operations
Tate & Lyle deal progresses with significant synergies.
Advances: Full-year 2026 adjusted EPS guidance $10.45 to $11.15
Q2 beat and reaffirmed guidance support growth objectives.
M&A call provides insights into strategic growth plans.
Acquisition of Tate & Lyle aligns with growth objectives.
Advances: Complete acquisition of Tate & Lyle and integrate operations
Completion of Tate & Lyle acquisition is a major milestone.
Advanced talks indicate strong commitment to growth strategy.
Threatens: Improve operational reliability at Argo plant and Food & Industrial Ingredients…
Operational issues at Argo facility impact earnings.